



Published on *British Columbia Drug and Poison Information Centre (BC DPIC)* (<http://www.dpic.org>)

[Home](#) > [Drug Product Listings](#) > [Suvorexant](#) > [Printer-friendly PDF](#)

Suvorexant

Trade Name:

Belsomra

Manufacturer/Distributor:

Merck Canada Inc.

merck.ca

Classification:

Hypnotic

ATC Class:

N05CM19 - suvorexant

Status:

active

Notice of Compliance (yyyy/mm/dd):

2018/11/29

Date Marketed in Canada (yyyy/mm/dd):

2019/04/16

Presentation:

Tablet: 10 mg. DIN: 02483513

Tablet: 15 mg. DIN: 02483521

Tablet: 20 mg. DIN: 02483548

Comments:

For treatment of insomnia. It is an orexin receptor antagonist. The orexin neuropeptide signaling system is a central promoter of wakefulness. Orexin producing neuronal cell bodies are localized specifically in the hypothalamus and project to the wakefulness mediating neurons of the brain. Suvorexant is thought to suppress wake drive by blocking the binding of the wake-promoting neuropeptides orexin A and orexin B to OX1R and OX2R reversibly.

Source:

Product monograph

Keywords: suvorexant

insomnia

Access:

public

Back to:

Please note - this is not a complete list of products available in Canada. For a complete list of drug products marketed in Canada, visit the [Health Canada Drug Product Database](#)

Status:

<Any> ?

Search Terms:

Apply

A (37) | B (20) | C (24) | D (37) | E (40) | F (12) | G (11) | H (9) | I (24) | K (1) | L (26) | M (12) | N (7) | O (12) | P (28) | R (14) | S (27) | T (33) | U (4) | V (13) | W (2) | Z (4)

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Tobramycin</u>	TOBI Podhaler	Antibiotic	2011/05/02
<u>Tocilizumab</u>	Actemra	Interleukin-6 inhibitor	2010/05/26
<u>Tolvaptan</u>	Samsca	Vasopressin V2 receptor antagonist	2011/09/22
<u>Tolvaptan</u>	Jinarc	Vasopressin V2-receptor antagonist	2015/06/01
<u>Trabectedin</u>	Yondelis	Antineoplastic agent	2010/08/04
<u>Tramadol</u>	Tridural	Analgesic	
<u>Tramadol</u>	Zytram XL	Opioid analgesic	2011/03/01
<u>Tramadol</u>	Ultram	Opioid analgesic	2010/05/01
<u>Tramadol</u>	Durela	Narcotic	2012/03/19
<u>Trastuzumab deruxtecan</u>	Enhertu	Antineoplastic agent	2021/04/15
<u>Trastuzumab emtansine</u>	Kadcyla	Antineoplastic agent	2013/09/27
<u>Trazodone</u>	Desyrel	Antidepressant	2010/05/14
<u>Tripolidine + codeine + pseudoephedrine + guaifenesin</u>	CoACTIFED Expectorant	Antitussive	2012/11/26
<u>Tucatinib</u>	Tukysa	Antineoplastic agent	2020/10/08
<u>Ulipristal</u>	Fibristal	Selective progesterone receptor modulator (SERM)	
<u>Ulipristal acetate</u>	Fibristal	Selective progesterone receptor modulator	2013/07/23
<u>Ulipristal acetate</u>	Ella	Contraceptive	2015/09/01
<u>Upadacitinib</u>	Rinvoq	Disease-modifying antirheumatic agent	2020/01/16

<u>Generic Name</u>	<u>Common Trade Name(s)</u>	<u>Classification</u>	<u>Date Marketed in Canada (yyyy/mm/dd)</u>
<u>Vandetanib</u>	Caprelsa	Receptor tyrosine kinase inhibitor (antineoplastic agent)	2012/01/24
<u>Vardenafil</u>	Staxyn	Phosphodiesterase Type 5 Inhibitor	2011/08/29
<u>Varenicline</u>	Champix	Smoking cessation aid	2007/04
<u>Vedolizumab</u>	Entyvio	Immunosuppressive agent	2015/04/21
<u>Velaglucerase alfa</u>	Vpriv	Enzyme replacement for treatment of Gaucher disease	2010/11/22
<u>Vemurafenib</u>	Zelboraf	Protein kinase inhibitor	2012/03/06
<u>Vemurafenib</u>	Zelboraf	Antineoplastic agent	2012/02
<u>Venetoclax</u>	Venclexta	Antineoplastic agent	2016/10/31
<u>Vilazodone</u>	Viibryd	Antidepressant	2015/07/16
<u>Vitamin C</u>	Prevegyn	Gynecological anti-infectives and antiseptics	2011/01
<u>Voretigene</u>	Luxturna	Cellular and gene therapy	2020/10/13
<u>Vorinostat</u>	Zolinza	Histone deacetylase inhibitor, anti-neoplastic agent	2009/06/17
<u>Vortioxetine</u>	Trintellix	Antidepressant	2014/10/28
<u>Warfarin</u>	Coumadin	Anticoagulant	2020/04/23
<u>White birch extract (Betula verrucosa)</u>	Itulatek	Allergy immunotherapy	2020/09/28
<u>Zafirlukast</u>	Accolate	Leukotriene modifier for asthma	
<u>Zolpidem</u>	Sublinox	Hypnotic	2011-12-07
<u>Zoster vaccine</u>	Zostavax	Vaccine	2009/08/11

« first? previous ? 4 5 6 7 8 9 10 11 12 next ? last »

We are grateful to all the First Nations who have cared for and nurtured the lands and waters around us for all time, including the x?m??k??y??m (Musqueam), Sk?wx?wu?7mesh U?xwumixw (Squamish Nation), and s?l?flw?ta? (Tsleil-Waututh Nation) on whose unceded and ancestral territory our centre is located.

All material found on the BC Drug and Poison Information Centre (DPIC) website is provided for informational purposes only. It is *not* meant to replace the expert advice of a healthcare professional such as a physician, pharmacist, nurse or qualified poison specialist. Use of this site is governed and restricted by specific terms of use. Please review the **full terms and conditions** below prior to using the DPIC website. In the event of a poisoning emergency, call your local poison control centre immediately. Portions of this web site are intended for healthcare professionals. Interpretation and application of information may require more detailed explanation than contained herein, particularly regarding any clinical information that is found in or linked to this site. Patients are advised to consult their health care provider regarding diagnosis and treatment, and for assistance in interpreting these materials and applying them in individual cases.

Terms and Conditions

Source URL (retrieved on 2025-05-14 20:22): <http://www.dpic.org/druglisting/suvorexant>